What Citralka Treats: Main Uses and Benefits

Citralka is used in contexts involving high acidity, particularly within the urinary system, where supportive symptomatic management is appropriate. The medication is commonly used across conditions presenting with acute or episodic manifestations related to acid-base imbalance. Its therapeutic applications include addressing conditions related to urolithiasis and metabolic acidosis.

It is applied across domains where additional symptomatic support is needed, primarily for managing conditions associated with specific kidney and bladder stones (such as uric acid and cystine stones), symptoms of painful or difficult urination (dysuria), and systemic imbalance in conditions like gout and certain types of metabolic acidosis.

Support for Symptom Management

The medicine is applied in addressing systemic imbalance that supports the patient during difficult episodes by easing the overall symptom burden. It contributes to maintaining a sense of stability when symptoms are more noticeable.

---

Quick Fact: Support for Symptom Management
Citralka is used in clinical settings that involve acute or unstable symptom patterns, and may assist with controlling crystal formation associated with uric acid or cystine stones.

Regulatory References

1. Pfizer Product Labeling for Disodium Hydrogen Citrate Syrup

Citralka, a systemic alkalinizing agent (Sodium Acid Citrate/Disodium Hydrogen Citrate), has strict eligibility criteria defined by regulatory bodies. Eligibility is primarily restricted by the drug’s potential to increase alkalinity and its high sodium content.

Populations For Whom Use is Contraindicated

Use of this medicine is absolutely prohibited in patients with the following conditions, as stated in official regulatory labeling:

• Severe Renal Impairment (including anuria, oliguria, or azotemia).
• Untreated Adrenocortical Insufficiency (Addison’s disease).
• Severe Myocardial Damage or uncontrolled Congestive Heart Failure.
• Acute Dehydration or pre-existing Hyperkalemia.
• Patients on a strict Sodium-Restricted Diet.

---

Age-Specific and Conditional Eligibility

Population	Eligibility Status (Regulatory Labeling)
Pediatric Patients	Safety and effectiveness have not been established in US labeling. Use in children must be determined by a physician.
Geriatric Patients	Use with caution is advised due to the greater likelihood of reduced renal function in older adults.
Pregnancy/Lactation	Safety has not been established. Use is conditional; only considered when benefits outweigh potential risks.
Impaired Renal Function	Severe impairment is contraindicated. Less severe cases require caution and periodic monitoring of serum electrolytes.

These restrictions ensure the medicine is only used by populations whose renal and cardiovascular systems can safely manage the added sodium and alkali load.

Interactions with other medicines and products

The primary concern regarding interactions with disodium hydrogen citrate (Citralka) is its effect on urinary pH, which can alter the elimination and exposure of several co-administered medicines. Official regulatory information describes two main categories of interactions:

1. Interactions via Altered Drug Elimination

By increasing the pH of the urine, disodium hydrogen citrate affects the rate at which other drugs are excreted by the kidneys. This pH-dependent change results in specific constraints for several drug classes:

• Increased Excretion (Decreased Effect): The plasma levels of weakly acidic drugs may be decreased due to enhanced renal excretion. This applies to certain antimicrobial agents (tetracyclines), salicylates, and the antidiabetic drug chlorpropamide. Co-administration may reduce the therapeutic effect of these medicines.
• Decreased Excretion (Increased Effect): The plasma levels of weakly basic drugs may be increased due to reduced renal excretion. This applies to medicines such as quinidine (an antiarrhythmic) and amphetamines, potentially leading to increased systemic exposure.

2. Interactions via Enhanced Absorption

The citrate component can enhance the gastrointestinal absorption of aluminum from co-administered aluminum-containing antacids. Concurrent administration of aluminum antacids and citrate salts is not recommended, particularly in individuals with impaired renal function. If concurrent use is unavoidable, close monitoring is necessary due to the risk of increased serum aluminum levels.

Citralka (Disodium Hydrogen Citrate) exerts its action through pharmacodynamic mechanisms centered on the modulation of acid-base balance and subsequent physicochemical changes within the urinary system. Following systemic absorption, the citrate component is metabolized primarily in the liver, leading to the generation of bicarbonate ( HCO3^-) ions. This bicarbonate increases the concentration of free bicarbonate excreted into the renal filtrate.

This sustained elevation of HCO3^- concentration within the tubular fluid results in a dose-dependent increase of the urinary pH, a process known as physiological alkalization. This pH shift directly modifies the solubility of specific metabolic byproducts. The increase in pH promotes the ionization of uric acid into the highly soluble urate ion and enhances the solubility of cystine. These changes decrease the supersaturation of these metabolites in the urine, consequently influencing the kinetics of their renal clearance and excretion.

Citralka is administered exclusively via the oral route as a liquid solution or syrup. The administration protocol involves a specific preparation step: the container must be shaken well immediately prior to measuring the dose. The prescribed volume must then be adequately diluted with water or milk before consumption.

The standard adult regimen involves a single dose volume ranging from 10 mL to 30 mL, which is typically administered four times daily (Q.I.D.). The timing of intake is critical, as doses are specifically scheduled to be taken after meals and once more at bedtime. This specific timing supports continuous maintenance of the target effect throughout a 24-hour period.

The precise dose volume is not a static regimen but is subject to titration—meaning the volume is adjusted by a healthcare provider based on monitoring of body chemistry. Citralka is intended for use in conditions that require the long-term maintenance of an alkaline state.

For specific populations, the administration rules vary: children between 6 and 12 years old have a lower dose volume, usually 10 mL to 15 mL, administered three to four times daily. Furthermore, use in patients who exhibit low urinary output requires caution and must only be applied under direct medical supervision.

Research evidence / Overview of Studies for Citralka

Evidence for Use in Managing Urinary Acidity and Stone Formation (Urolithiasis)

Citralka, which is a source of alkali, research has explored its role in managing conditions characterized by high acidity in the urinary system, such as uric acid and cystine stones. The research in this area includes systematic reviews as well as observational studies that evaluate how the medicine is used in research contexts involving fluctuating or unstable symptoms. The research examined outcomes, including how this treatment was associated with changes in urinary pH (a key chemical measure) and the rates of stone formation or recurrence over defined time intervals.

Studies in this area reported measurements showing that the administration of citrate salts was associated with a shift toward less acidic urinary pH. Some trials also described patterns of observed changes in stone size in specific groups of patients receiving alkali therapy. However, the findings related to recurrence rates in the studies showed some variability and often depended on the specific type of citrate salt used. What remains uncertain is that the existing evidence is often heterogeneous, and there is a lack of direct, large-scale, randomized controlled trials (RCTs) specifically comparing Disodium Hydrogen Citrate to a non-treatment option.

---

Evidence for Use in Systemic Acid-Base Balance (Metabolic Acidosis)

This medicine research has explored its use as a systemic alkalinizing agent, relevant in evidence describing how the body manages chronic acid-base imbalances, known as metabolic acidosis. Research in this area includes clinical trials and pharmacological studies where the main focus was on measuring changes in key biomarkers, such as serum bicarbonate concentration and arterial blood pH levels. Outcomes monitored physiological strain or stress in populations, often those with conditions like Chronic Kidney Disease (CKD).

Studies reported measurements confirming that the use of citrate salts was associated with an elevation in serum bicarbonate concentration. Researchers examined outcomes related to systemic or functional imbalance, specifically looking at long-term patterns in the progression of CKD following alkali therapy. However, findings from trials examining the relationship between alkali therapy and CKD progression showed some variability. Evidence is limited regarding the specific research parameters used in trials that have achieved consistent, long-term stability in systemic pH. Long-term effects are not fully established for this specific formulation, and data for certain groups remain limited.

Key Studies & References CITRALKA (disodium hydrogen citrate) Liquid - Therapeutic Indications and Warnings

Common questions about Citralka (FAQ)

Q: Is it true that Citralka causes stomach upset?

Official product labeling indicates that the most commonly reported adverse reactions involve the stomach and digestive system. These include nausea, vomiting, diarrhea, and abdominal discomfort. Such events are typically documented in official safety information for review by a healthcare provider.

Q: Does Citralka interact with common supplements like Vitamin C?

Citralka works by increasing the pH (making the urine less acidic), which can potentially alter how the body processes other substances. For this reason, official sources describe the necessity of discussing all supplements, including Vitamin C (ascorbic acid), with a healthcare provider, as its excretion may be affected. This ensures any potential interactions can be monitored.

Q: Can Citralka be taken with pain relievers like ibuprofen?

Regulatory documents explain that the increase in urinary pH caused by Citralka can lead to decreased plasma levels of certain weakly acidic medicines, potentially reducing their effect. This applies to drugs like salicylates, which are a class of pain reliever. Due to potential interactions, regulatory information recommends discussing co-administered medicines with a healthcare provider.

Q: What if I forget to use Citralka one day?

Official patient instructions provide guidance for a missed dose. If a dose is forgotten, it can be taken once remembered, but only if it is not too close to the next scheduled time. If it is nearly time for the next dose, labeling typically describes skipping the missed dose entirely to avoid doubling the amount.

Q: Is Citralka generally considered safe for older adults?

Official regulatory information advises using this medicine with caution in older adults. This warning is based on the increased likelihood of reduced kidney function in geriatric patients. Official guidance requires careful monitoring by a healthcare provider.

Q: Can Citralka be used by teenagers?

The safety and effectiveness of this medicine have not been specifically established in US labeling for all pediatric patients, including teenagers. Official documents require that use in this age group be medically determined and monitored by a healthcare professional.

Q: Are there any studies looking at long-term use of Citralka?

Research has examined the role of Citralka in conditions that require long-term maintenance of an alkaline state. However, official regulatory overviews note that evidence from available trials regarding the long-term effects of this specific formulation is limited and not fully established.

Q: Can I mix Citralka with juice instead of water?

The official administration protocol requires the measured dose to be adequately diluted before consumption. Regulatory-aligned patient information typically advises using water or milk for dilution. Some sources also mention fruit juice as an acceptable alternative for dilution.

Q: Does Citralka make other medicines less effective?

Yes, official regulatory warnings describe how Citralka can potentially reduce the effectiveness of other medications. By making the urine less acidic, it can enhance the renal excretion of certain weakly acidic drugs, which may lead to a decreased therapeutic effect of those co-administered medicines.

Q: Is Citralka a type of antibiotic?

No, Citralka is not classified as an antibiotic. Regulatory documents define it as a Systemic Alkalinizing Agent, meaning its primary action is to reduce acidity in the body and urine.

Q: How quickly should I feel a difference after starting Citralka?

According to patient information aligned with regulatory documents, the effect of the medicine typically begins quickly, within a few minutes after consumption. The resulting change in pH usually lasts for approximately four to six hours.

Q: Is it okay to take Citralka every day for a long time?

Citralka is designed to be used for the long-term maintenance of an alkaline state in specific conditions. Because of its systemic effects, use requires caution in patients with impaired kidney function. Official guidance describes the requirement for periodic monitoring of serum electrolytes in patients with kidney disease.

Q: Are there any common foods I need to avoid while using Citralka?

Official regulatory documents state that the medicine is absolutely prohibited (contraindicated) for patients on a strict sodium-restricted diet due to the drug's sodium content. No other common foods are explicitly listed for avoidance in the main regulatory documents.

Q: Can Citralka cause a headache?

Headache is not listed among the most common adverse reactions in official labeling. Any new or worsening symptoms should be brought to the attention of a healthcare provider.

Q: Is Citralka safe to use if I have diabetes?

Caution is advised when this medicine is used by patients with diabetes. Because the medication is a syrup, it may contain sugar. The official precaution advises consultation with a healthcare provider regarding the formulation's appropriateness for their needs.

Q: Is there a generic version of Citralka available?

Yes, the active ingredient in Citralka, which is Disodium Hydrogen Citrate, is widely available. This means the ingredient can be found under various different brand names, suggesting the availability of generic alternatives on the market.

Q: Does the time of day matter when using Citralka?

Yes, the timing of intake is considered critical. Doses are specifically scheduled to be taken after meals and once more at bedtime. This specific timing is detailed in regulatory documents to support the continuous maintenance of the desired alkaline effect throughout a 24-hour period.

Q: Can Citralka be used during fasting?

Dosing is scheduled to occur after meals. This specific timing is advised in patient instructions to help reduce the potential risk of stomach upset. Regulatory guidance specifies that any deviation from the recommended schedule should be discussed with a healthcare provider.

Q: Does Citralka contain sugar or artificial sweeteners?

The formulation is a syrup, which is a key reason patients with conditions like diabetes are advised to exercise caution. The product may contain sugar, and official caution advises patients to discuss the composition with their healthcare provider.

Q: What are the signs that Citralka is working for me?

The intended therapeutic effect of Citralka is measured chemically. The primary sign that the medicine is working is a shift toward a less acidic urinary pH, meaning the acidity level is reduced. This pH value is typically monitored by a healthcare provider.

Q: Can Citralka affect my sleep?

Official labeling lists tiredness as a possible side effect of the medication. Despite this, one dose is specifically scheduled to be taken once at bedtime. Any related symptoms should be brought to the attention of a healthcare provider.

Q: Are allergic reactions to Citralka common?

Regulatory safety documents indicate that a very serious allergic reaction to this drug is considered rare. Immediate medical attention is the protocol described in safety documents if serious symptoms such as rash, severe dizziness, or difficulty breathing occur.

Q: Is it true that taking Citralka makes you thirsty?

Extreme thirst is not a common side effect but is listed in safety warnings as one of the potential signs of a more serious effect. Specifically, it can indicate high sodium levels in the blood. Regulatory guidance requires immediate reporting of this symptom to a healthcare provider.

Q: Does Citralka affect liver function tests?

The active component is metabolized primarily in the liver. Official product information therefore advises caution when the medicine is used in patients with existing liver impairment. The official protocol includes the possibility of liver function monitoring in such cases.

Q: Is Citralka used to treat gout?

Yes, the regulatory-approved uses of Citralka include the management of conditions like gout. Its alkalinizing effect is utilized because it helps the body eliminate excess uric acid, which is a key factor in these conditions.

Q: Can Citralka cause dizziness or lightheadedness?

Dizziness is not listed among the most common adverse effects. However, severe dizziness is specifically listed in safety documents as a rare symptom that may indicate a serious allergic reaction.

Q: Does taking Citralka affect my ability to drive or operate machinery?

Official information for similar formulations does not indicate an expected effect that would impair the ability to drive or use machinery. Official information notes that possible side effects of this medicine include tiredness.

Q: How should I store Citralka at home?

Official instructions require the medicine to be stored at controlled room temperature, typically between 20 °C and 25 °C (68 °F and 77 °F). The container must be kept tightly closed and protected from both light and excessive heat. As with all medicines, it must be kept out of the reach of children.

Storage and Disposal of Citralka (Disodium Hydrogen Citrate Liquid)

Citralka must be stored according to official regulatory requirements to ensure product stability and safety.

---

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store at controlled room temperature, between 20°C and 25°C (68°F and 77°F).
Protection	Protect from light and excessive heat; Do not freeze.
Container	Keep the container tightly closed and store in the original container.
Child Safety	Mandatory to keep out of the reach and sight of children.

---

Disposal Instructions

Expired or unused Citralka must be disposed of according to local regulations for pharmaceutical waste. Do not flush the medication down the toilet or pour it into drains.